Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.

ABSTRACT:

Objective

No standard postoperative adjuvant chemotherapy has ever been established in node-positive esophageal squamous cell carcinoma (ESCC). This is a study to explore the effect of postoperative paclitaxel (PTX) and cisplatin (DDP) in lymph node-positive, completely resected thoracic ESCC patients.

Methods

We conducted a prospective phase II trial. Patients had pathologically node-positive thoracic ESCC with negative margins. Outcomes of disease-free survival (DFS) and overall survival (OS) were compared with a matched historical control cohort. The postoperative chemotherapy regimen consisted of 4 to 6 cycles of PTX 150 mg/m² administered intravenously on d 1 followed by DDP 50 mg/m² on d 2 every 14 d.

Results

Forty-three patients were accru

SUBMITTER: Zhang L 

PROVIDER: S-EPMC5422417 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature